Corporate News - Beijing Beilu Pharmaceutical Co., Ltd.

Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong

2022/12/27

In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...

VIEW_MORE

Beilu Yikang, the R&D Subsidiary of Beilu Pharmaceutical, Was Officially Launched

2022/10/12

"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...

VIEW_MORE

Beilu Pharma Established a Wholly-owned R&D Subsidiary

2022/09/06

Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...

VIEW_MORE

Beilu Pharmaceutical has been awarded "Beijing Advanced Unit of Adverse Drug Reactions Daily Monitoring" for 4 consecutive years.

2022/08/04

Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...

VIEW_MORE

Beilu's Iopamidol Injection Won the Bid for China's Pharmaceutical Centralized Procurement

2022/07/15

On July 12, 2022, Beilu participated in the seventh batch of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use Joint Procurement Off...

VIEW_MORE

Beilu Pharma's Gadobutrol Injection Has Been Approved By NMPA

2022/04/08

Beijing Beilu Pharmaceutical Co., Ltd. (300016) announced today that Gadobutrol injection has obtained the "Drug Registration Certificate" issued by the NMPA（National Medial Production Administr...

VIEW_MORE

Beilu Pharma Invested 192 Million Yuan In Cangzhou Raw Material Production Project

2022/03/22

The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...

VIEW_MORE